Molecular targets and biological modifiers in gastric cancer

被引：52

作者：

Carneiro, Fatima ^{[1
,2
,3
]}

Oliveira, Carla ^{[1
,2
]}

Leite, Marina ^{[1
]}

Seruca, Raquel ^{[1
,2
]}

机构：

[1] Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal

[2] Univ Porto, Fac Med, P-4100 Oporto, Portugal

[3] Hosp Sao Joao, Dept Pathol, Oporto, Portugal

来源：

SEMINARS IN DIAGNOSTIC PATHOLOGY | 2008年 / 25卷 / 04期

关键词：

Gastric cancer; Molecular targets; Mutation; E-cadherin (CDHI); Microsatellite instability;

D O I：

10.1053/j.semdp.2008.07.004

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 [基础医学];

摘要：

The overall survival of gastric cancer patients remains poor despite efforts and advances in its prevention, diaposis, and treatment. The development of new therapies is crucial for the effective control of this disease. An increasing number of genetic and epigenetic alterations have been associated with distinct histological types of gastric cancer. In this review, we will discuss the involvement of E-cadherin, EGFR, ERBB2, MMR genes, KRAS, and PIK3CA in the development and progression of gastric cancer and their role as biomarkers or as novel putative targets for therapy. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：274 / 287

页数：14

共 162 条

[1]

Aarnio M, 1997, INT J CANCER, V74, P551, DOI 10.1002/(SICI)1097-0215(19971021)74:5<551::AID-IJC13>3.0.CO

[2]

2-9

[3]

THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].